The sales are routine post-exercise liquidity events at trivial scale. No bearish read-through. Monitor for any material insider buying (which would be a stronger signal) or for upcoming earnings/catalyst news that could shift sentiment.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $91.84entry
- T+1 · 6mo ago +0.71%α +0.31% · $92.49
- T+5 · 5mo ago +2.36%α +6.18% · $94.00
- T+20 · 5mo ago +36.76%α +37.76% · $125.59
- T+60 · 3mo ago +8.62%α +6.12% · $99.75
Price Chart
How similar events traded
Executive Summary
Mirum Pharmaceuticals CEO Christopher Peetz and Director Saira Ramasastry sold a combined $644K in open-market sales on June 1, 2026, following a cluster of non-cash derivative exercises by multiple directors on May 29. The sales represent ~0.01% of MIRM's $5.9B market cap, trivial in proportion, and are likely liquidity-driven after option exercises, not a bearish signal. The stock has strong analyst support (95% bullish) and the cluster lacks material dollar weight.
Key Financial Metrics
Key Facts
- CEO Peetz sold 2,602 shares at $94.64 for $246K on June 1, 2026
- Director Ramasastry sold 3,977 shares at $100 for $398K on June 1, 2026
- Both sales followed non-cash derivative exercises on May 29 (directors) and June 1 (CEO)
- Total open-market sales of $644K represent ~0.01% of MIRM's $5.9B market cap
- Analyst consensus is 95% bullish (18 Buy, 1 Hold, 0 Sell)
- No open-market purchases in the cluster
Financial Impact
Total insider sales of $644K, immaterial relative to $5.9B market cap
Risk Factors
- Insider sales could accelerate if stock continues to appreciate, but no evidence of coordinated selling
- No purchases in cluster, lack of bullish insider signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MIRM-1780444246058 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers